ArticleMolecules (Basel, Switzerland)2022
α-Linolenic Acid Suppresses Proliferation and Invasion in Osteosarcoma Cells via Inhibiting Fatty Acid Synthase.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Current Study of Alpha-Mangostin in Breast Cancer Therapy: Antioxidant Mechanisms and Redox Modulation from In Silico to In Vivo Studies.Antioxidants (Basel, Switzerland) · 2026Review
- Machine Learning-Assisted Plasma Metabolomics Identifies a Five-Metabolite Panel for Colorectal Cancer Detection.ACS omega · 2026Article
- RHBDL2 drives lipid metabolic reprogramming in osteosarcoma via USP3-mediated deubiquitination of PPT1.Cell death & disease · 2026Article
- Multi-omics integration analysis reveals metabolic changes during sika deer antler growth.BMC genomics · 2026Article
- Apoptotic Effects ofMolecules (Basel, Switzerland) · 2026Article
- Single-cell transcriptomic analysis reveals fatty acid metabolic heterogeneity and identifies DKK1 as a candidate prognostic factor in osteosarcoma.Frontiers in endocrinology · 2026Article
- Alpha-linolenic acid in cancer: a predictive fate-switch framework for tumor lipid reprogramming.Frontiers in oncology · 2026Article
- Phytochemical Profile and Bioactive Evaluation ofInternational journal of molecular sciences · 2025Article
- Chemical profiling and anticancer activity of Alnus incana dichloromethane fraction on HeLa cells via cell cycle arrest and apoptosis.BMC complementary medicine and therapies · 2025Article
- Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets.Journal of bone oncology · 2025Review
- SPICE1 promotes osteosarcoma growth by enhancing the deubiquitination of FASN mediated by USP10.Journal of translational medicine · 2025Article
- Ubiquitination in lipid metabolism reprogramming: implications for pediatric solid tumors.Frontiers in immunology · 2025Review
- Spatiotemporal evolutionary process of osteosarcoma immune microenvironment remodeling and C1QBP-driven drug resistance deciphered through single-cell multi-dimensional analysis.Bioengineering & translational medicine · 2024Article
- The Effect of Mulberry Silage Supplementation on the Carcass Fatness and Long-Chain Fatty Acid Composition of Growing Lambs Compared with Traditional Corn Silage.Foods (Basel, Switzerland) · 2024Article
- Differences in Milk Fatty Acids Profile of Two Breeds of Water Buffaloes Explained by Their Gastrointestinal Microbiota.Animals : an open access journal from MDPI · 2024Article
- Article
- Matcha Green Tea: Chemical Composition, Phenolic Acids, Caffeine and Fatty Acid Profile.Foods (Basel, Switzerland) · 2024Article
- Global research trends and hotspots in metabolomics of osteosarcoma: a decade-spanning bibliometric and visualized analysis.Frontiers in immunology · 2024Article
- Protective Effect of Alpha-Linolenic Acid on Human Oral Squamous Cell Carcinoma Metastasis and Apoptotic Cell Death.Nutrients · 2023Article
- Metabolic reprogramming in osteosarcoma.Pediatric discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Fatty acid synthase (FASN) is highly expressed in multiple types of human cancers and is recognized as one of the targets for treating cancer metastasis. α-Linolenic acid is an omega-3 essential fatty acid and it possesses various biological activities. The present study was designed to reveal the effects of α-linolenic acid on osteosarcoma and to reveal whether the mechanism of α-linolenic acid in anticancer activity may be related to FASN inhibition. The cytotoxicity of α-linolenic acid was assessed in osteosarcoma MG63, 143B, and U2OS cells. Cell viability was detected by the MTT assay. The protein expression level was detected by western blotting. Flow cytometry, Annexin V/propidium iodide dual staining, and Hoechst 33258 staining were performed to assess the apoptotic effects. Wound healing assay was applied to detect the inhibitory effect of α-linolenic acid on osteosarcoma cells migration. The results showed that α-linolenic acid downregulated FASN expression. α-Linolenic acid inhibited osteosarcoma cell proliferation and migration in a dose-dependent manner. In addition, α-linolenic acid regulated endoplasmic reticulum transmembrane receptors and signal protein expression in osteosarcoma cells. The findings of the present study suggested that α-linolenic acid suppresses osteosarcoma cell proliferation and metastasis by inhibiting FASN expression, which provides a basis as a potential target for osteosarcoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.